Wyeth (WYE. N) said that the deadline set for the review of its advanced vaccine, Prevnar 13, to prevent pneumococcal meningitis in infants and toddlers, has been extended by three months by the Food and Drug Administration, following the submission of additional data on the vaccine's formulation.

The U. S. Justice Department said that it along with 16 states has joined in two whistleblower lawsuits against Wyeth, filed in federal court in Massachusetts.

The U.S. Supreme Court ruled Wednesday that patients harmed by medication can sue the pharmaceutical companies for not listing known dangers on the products warning labels approved by federal regulators.

According to the Sunday reports by the New York Times and Wall Street Journal, Pfizer's finalized deal with Wyeth is likely to be announced on Monday, before the markets open. Pfizer was reportedly making rushed attempts on Sunday, to secure financing for its $68 billion acquisition of Wyeth.

By far the biggest of the takeover bids in recent times - the prospective buyout bid by Pfizer Inc for buyout of its rival Wyeth for a monstrously huge $60 billion - will likely come through!

Elsevier is investigating allegations over ghost-written articles paid for by Wyeth Pharmaceuticals, in favour of its’ hormone replacement medications, which the publisher published in one of his medical journals.
 

The pharmaceutical giant, Wyeth paid a medical writing company to write favorable articles supporting the use of its HRT drug Prempro. The US Senator Charles Grassley, made the revelation about the unfair tactics of the pharmaceutical company.

Mr. Grassley has been probing the case for quite sometime.